Novo Nordisk A/S reported a 24% increase in sales to DKK 133.4 billion for H1 2024 and an operating profit of DKK 57.8 billion, up 18%. This growth is driven by a 32% rise in GLP-1 diabetes treatments; the filing details developments up to June 30, 2024.